Guggenheim Maintains Buy on SCYNEXIS, Raises Price Target to $33
Guggenheim analyst Vamil Divan maintains SCYNEXIS (NASDAQ:SCYX) with a Buy and raises the price target from $24 to $33.
Read original at benzingaStocks · News reference
UPDATE: SCYNEXIS Q2 Adj. EPS $(0.57) Misses $(0.51) Estimate, Sales $235.000K Beat $80.330K Estimate
SCYNEXIS (NASDAQ:SCYX) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.51) by 11.76 percent. This is a 49.11 percent increase over losses of $(1.12) per share from the
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 10, 2026, 10:31 PM
- Checked
- Aug 10, 2026, 10:31 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
SCYNEXIS Q2 EPS $0.63 Beats $(0.64) Estimate, Sales $235.000K Beat $80.330K Estimate
SCYNEXIS (NASDAQ:SCYX) reported quarterly earnings of $0.63 per share which beat the analyst consensus estimate of $(0.64) by 198.44 percent. This is a 156.25 percent increase over losses of $(1.12) per share from the
Read original at benzingaWatching SCYNEXIS; Shares Trading Higher, Hearing GSK Is Close To Relaunching BREXAFEMME With The Co, FDA Updates BREXAFEMME Label With Pediatric Use Information And Revised Patient Safety Guidance
https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=2636#
Read original at benzinga